Octagon Capital Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Octagon Capital Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-148,000	Closed	-$6.99M	–	29
2025 Q2	$6.99M	Sell	148,000 -148,000	-50%	-$6.03M	1.53%	23
2025 Q1	$11.6M	Buy	+296,000	New	+$12.8M	2.24%	18
2022 Q1	–	Sell	-400,000	Closed	-$3.96M	–	29
2021 Q4	$3.96M	Hold	400,000	–	–	0.77%	21
2021 Q3	$3.95M	Hold	400,000	–	–	0.97%	23
2021 Q2	$4.13M	Hold	400,000	–	–	0.86%	29
2021 Q1	$4.08M	Hold	400,000	–	–	1.54%	24
2020 Q4	$4.55M	Buy	+400,000	New	+$4.25M	1.58%	22

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Octagon Capital Advisors's MLTX Position: Q3 2025 in Review

Octagon Capital Advisors sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 148,000 shares — an estimated $6.99M sold.

Octagon Capital Advisors first reported a position in MLTX in Q4 2020 and held it in 7 quarters. The position peaked at $11.6M in Q1 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

Octagon Capital Advisors reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
Octagon Capital Advisors sold 148,000 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $6.99M.
Octagon Capital Advisors first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 7 quarters.
Octagon Capital Advisors's MoonLake Immunotherapeutics position peaked at $11.6M in Q1 2025.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Octagon Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.